Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, is substantially eliminated from the body within 23 weeks of discontinuation
Weight loss was still ongoing at week 48, suggesting potential for even greater results with longer treatment
Angiogenic, anti-inflammatory, and neuroprotective effects have all been documented across multiple preclinical delivery routes
"However, it is a temporary program
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
